Medicare to review use of anemia drugs

03/15/2007 | NYTimes.com

Medicare officials plan to review the use of three anemia drugs in light of concerns about potentially harmful side effects. The review could determine whether Medicare continues to pay for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ